Clinical-stage biotech developing oral small molecule drugs for obesity
Structure Therapeutics is a clinical-stage biopharma advancing oral GPCR-targeted small molecules for metabolic and cardiopulmonary disease. Its stack pairs GROMACS and PyTorch for computational chemistry with Medidata Rave, SAS and CDISC for trial data, and accelerating, senior-heavy hiring in ops plus a new Head of Data and External Manufacturing Director point to a push into late-stage studies and launch readiness.
Notable leadership hires: External Manufacturing Director, Medical Director, Head of Data
Structure Therapeutics, founded in 2017 and headquartered in South San Francisco, California, is a public clinical-stage biopharmaceutical company. It discovers and develops oral small molecule treatments for chronic conditions including obesity, diabetes, and cardiovascular and pulmonary diseases. Its pipeline targets GPCRs and is built using a structure-based drug discovery approach grounded in computational chemistry. The company employs 51–200 people and currently hires in the United States.
Structure Therapeutics uses Python, PyTorch, TensorFlow, scikit-learn and GROMACS for research, Medidata Rave, SAS and CDISC for clinical data, AWS, GCP and Azure for cloud, and NetSuite and Ramp for finance.
Yes. Hiring is accelerating and skews senior, centered on operations, with roles in data, research, finance and healthcare, plus leadership openings such as Head of Data, Medical Director and External Manufacturing Director.
Job posts point to multinational late-stage clinical studies, AI-powered data science tools for clinical research, CMC lifecycle management, clinical trial financial planning and commercial product launch plans.
Other companies in the same industry, closest in size
Structure Therapeutics's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.